Eli Lilly announced that its newly FDA‑approved oral GLP‑1 weight‑loss drug, Foundayo (orforglipron), is now available to patients in the United States. The pill can be purchased through Lilly’s direct‑to‑patient platform, retail pharmacies, and partner networks such as Weight Watchers Med+ and GoodRx, marking the first time an oral GLP‑1 therapy is accessible to U.S. consumers.
Foundayo received FDA approval on April 1 2026 and began shipping to pharmacies on April 6 2026. The April 9 launch makes it the first oral GLP‑1 medication in the U.S., expanding Lilly’s obesity‑drug lineup beyond its injectable offerings, Mounjaro and Zepbound, and positioning the company to capture patients who prefer a pill over injections.
The drug’s lowest dose is priced at $149 per month for self‑pay patients, matching the initial price of Novo Nordisk’s Wegovy pill. Analysts project Foundayo sales of approximately $1.55 billion in 2026, growing to about $14.8 billion by 2030, as the U.S. obesity market—estimated at 100 million adults—continues to expand and global demand reaches 1 billion people with obesity.
Lilly’s recent financial performance underscores the strategic importance of the launch. Q4 2025 revenue rose 43% to $19.3 billion, driven by strong demand for Mounjaro and Zepbound, while full‑year 2025 revenue reached $65.2 billion, a 45% increase YoY. The company has guided 2026 revenue to $80–$83 billion, reflecting confidence in continued growth of its obesity portfolio.
Management highlighted the significance of 2025 as a pivotal year for Lilly, noting that the company’s product launches and robust pipeline—such as the promising weight‑loss candidate retatrutide—are expected to sustain momentum. Analysts maintain a “Strong Buy” consensus, with a median price target of $1,260, indicating that the market views the launch as a positive catalyst for future earnings.
The Foundayo launch strengthens Lilly’s competitive stance in the rapidly expanding GLP‑1 market, offering a convenient oral alternative that could capture a sizable share of patients who prefer pills over injections. While the company faces valuation concerns and intense competition from Novo Nordisk, the addition of Foundayo, combined with its strong financial performance and pipeline depth, positions Lilly to capitalize on the growing obesity treatment market and drive long‑term shareholder value.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.